Trial Profile
A phase I/II study with docetaxel and gemcitabine in hormonal refractory metastatic prostate cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Nov 2005 New trial record.